

Epinex CEO Asked to Join ADA Board



Cure • Care • Commitment®

Asad Zaidi, Epinex's President and CEO, has been nominated as a board member of the Orange County Chapter of the American Diabetes Association (ADA). Mr. Zaidi will bring over 30 years of invaluable experience in the biomedical device industry to help further the ADA's mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

Epinex Applies for Government Grant

Fundraising during this economic recession continues to be a challenge for Epinex and many startup companies in the life sciences. In light of the tough economic climate, the Obama Administration has announced a \$1 billion tax credit/grant to support research with the potential to produce new therapies and create high-quality jobs. The Qualifying Therapeutic Discovery Project credit, created under the Affordable Care Act on March 23, 2010, will allow small firms with less than 250 employees to be reimbursed for up to fifty percent of the cost of qualifying research performed during 2009 and 2010. Epinex submitted a grant application early in July. The Department of Health and Human Services (HHS) will release determinations no later than October 29, 2010.

NEWLY CONSTRUCTED LABS UNDERGO STATE INSPECTION

Epinex has finalized the design and construction of its manufacturing spaces, including laboratories for wet/dry production and quality control, inventory and staging areas, and shipping and receiving areas. The GMP-compliant facility will be used to manufacture the G1A™ test cassettes in-house. An initial onsite inspection was performed by the Medical Device Safety Unit of the California Department of Public Health on May 11, 2010 in preparation for the Medical Device Manufacturing License. The inspector evaluated Epinex's quality systems, including all manufacturing spaces and processes, and found "no observations."




Dry Manufacturing Laboratory



R&D Laboratory



Wet Manufacturing Laboratory



Reagent Striper



Staging/Inventory Area



Clamshell Laminator

Corporate Office:

Epinex Diagnostics, Inc.
14351 Myford Rd., Unit J
Tustin, California 92780 USA
www.epinex.com

Corporate Finance:

Jeff Byrd, Vice President
Toll Free: (866) 592-3746
jeff@epinex.com



EPINEX DIAGNOSTICS INC.

CREATING A REVOLUTION IN BIOTECH-BASED DIAGNOSTICS

Epinex Patent Granted

The United States Patent and Trademark Office (USPTO) granted Epinex's main technology patent on February 9, 2010. The patent (US7659107B2) is for the first ever rapid glycosylated albumin test and instrument, which could redefine the way diabetes is monitored for over 250 million diabetics worldwide. Epinex's ground-breaking patent is the first step in establishing a new standard of care for diabetes, providing a monthly measurement of the protein damage that causes diabetes complications such as blindness, kidney failure, and heart disease.

Epinex Expands In-House Capabilities

Azra Zaidi, Epinex's director of Research and Development, has recently completed the Clinical Trial Certification program through the University of California, Irvine Extension. The curriculum provided comprehensive knowledge of coordinating, monitoring, and managing a clinical trial within the framework of good clinical practices and regulatory requirements. The certification will facilitate the design and implementation of large scale clinical trials for the Epinex G1A™ Rapid Diabetes Monitoring Index Test.

Experts Declare Gestational Diabetes Underdiagnosed

Research performed at Northwestern University's Feinberg School of Medicine has demonstrated that even small elevations in blood sugar during pregnancy can lead to sick and overweight babies that are predisposed to type 2 diabetes. Diabetes experts worldwide have developed new recommendations (published in the March issue of the ADA's journal, Diabetes Care) for the diagnosis of gestational diabetes that could triple the number of existing cases. Epinex's G1A™ test may provide a point-of-care testing solution to help alleviate the treatment burden on overwhelmed obstetricians' practices.



Patent for "Rapid Test for Glycosylated Albumin"

Epinex Attends Prestigious Clinical Meetings

ADA -- Epinex CEO, Asad Zaidi, and R&D Director, Azra Zaidi, attended the American Diabetes Association's (ADA) 70th Scientific Sessions in Orlando, FL from June 25-June 29. The ADA Scientific Session is the world's largest and most prestigious diabetes meeting, offering cutting-edge research and education for diabetes professionals. Program themes this year included Clinical Diabetes/Therapeutics and Healthcare Delivery & Economics.

AACC -- The Epinex Team will attend the American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo at the Anaheim Convention Center in California from July 25-July 29. The AACC boasts the world's largest laboratory conference, with about 20,000 registrants from more than 100 countries. With the vision to advance the application of clinical laboratory science to healthcare, the AACC offers a variety of programs that address the many technical and management challenges facing our industry.

Epinex Interns Graduate from UCI

Epinex proudly announces the graduation of three aspiring interns from the University of California in Irvine: Rachel Bohunis (Marketing/PR), John Scott (Engineering), and Charles Vo (Operations). Epinex's year-long internship program is a rigorous educational experience that incorporates both professional and personal development programs. The interns have been invited to fill full-time positions at Epinex.



Rachel Bohunis
Marketing/Public Relations
B.A. Business Economics



John Scott
Engineering
B.S. Computer Engineering



Charles Vo
Operations
B.A. Economics



EPINEX DIAGNOSTICS INC.

CREATING A REVOLUTION IN BIOTECH-BASED DIAGNOSTICS